| Title |
|
|
|
Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients
|
|
| Author |
|
|
|
|
|
| Abstract |
|
|
|
| Context and Objective: In preparation of future prevention trials, we aimed to identify predictors of 3-year diabetes onset among oral glucose tolerance test (OGTT)- and hyperglycemic clamp-derived metabolic markers in persistently islet autoantibody positive (autoAb+) offspring and siblings of patients with type 1 diabetes (T1D). Design: The design is a registry-based study. Setting: Functional tests were performed in a hospital setting. Participants: Persistently autoAb+ first-degree relatives of patients with T1D (n = 81; age 539 years). Main Outcome Measures: We assessed 3-year predictive ability of OGTT- and clamp-derived markers using receiver operating characteristics (ROC) and Cox regression analysis. Area under the curve of clamp-derived first-phase C-peptide release (AUC510min; min 510) was determined in all relatives and second-phase release (AUC120150min; min 120150) in those aged 1239 years (n = 62). Results: Overall, the predictive ability of AUC510min was better than that of peak C-peptide, the best predictor among OGTT-derived parameters (ROC-AUC [95%CI]: 0.89 [0.800.98] vs 0.81 [0.700.93]). Fasting blood glucose (FBG) and AUC510min provided the best combination of markers for prediction of diabetes within 3 years; (ROC-AUC [95%CI]: 0.92 [0.841.00]). In multivariate Cox regression analysis, AUC510min (P = .001) was the strongest independent predictor and interacted significantly with all tested OGTT-derived parameters. AUC510min below percentile 10 of controls was associated with 5070% progression to T1D regardless of age. Similar results were obtained for AUC120150min. Conclusions: Clamp-derived first-phase C-peptide release can be used as an efficient and simple screening strategy in persistently autoAb+ offspring and siblings of T1D patients to predict impending diabetes. | |
|
| Language |
|
|
|
English
|
|
| Source (journal) |
|
|
|
The journal of clinical endocrinology and metabolism. - Baltimore, Md |
|
| Publication |
|
|
|
Baltimore, Md : 2015
|
|
| ISSN |
|
|
|
0021-972X
|
|
| Volume/pages |
|
|
|
100:2(2015), p. 551-560
|
|
| ISI |
|
|
|
000353350900059
|
|
| Full text (Publisher's DOI) |
|
|
| |
|
| Full text (publisher's version - intranet only) |
|
|
| |
|